Muse Cell Therapy for Aortic Aneurysm Vascular Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vascular disorders such as aortic aneurysms are inadequate, particularly in early stages, as they often rely on vascular cell transplantation or gene therapy with insufficient therapeutic effects, and there is a need for a method to prevent and treat aneurysms through revascularization using a small dose of mesenchymal stem cells that can invade and differentiate into vascular cells at injured sites.
Innovation Solution
A cell product comprising SSEA-3-positive pluripotent stem cells derived from mesenchymal tissue, known as Muse cells, which can be administered via a blood vessel or directly to the injured site, allowing them to engraft, differentiate into vascular cells, and repair damaged blood vessels, thereby addressing vascular disorders including aortic aneurysms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vascular cell transplantation or gene therapy is used to treat aortic aneurysms, then therapeutic effect is achieved, but the treatment is insufficient and requires large doses or complex procedures
Solution Approach 1:
The patent changes the key parameter from cell type (vascular smooth muscle cells, endothelial cells) to pluripotent stem cells (Muse cells), and from large doses to small doses (1×10^3 to 1×10^6 cells), achieving both high therapeutic effect and treatment simplicity
Solution Approach 2:
Muse cells exhibit multi-functionality by differentiating into multiple vascular cell types (endothelial cells, smooth muscle cells, pericytes) and secreting multiple growth factors (VEGF, FGF, PDGF, TGF-β), thereby achieving comprehensive vascular repair with a single cell type
2Reliability
If MSCs are administered to treat aneurysms, then some therapeutic effect is observed, but the effect is not sufficient and requires large doses
Solution Approach 1:
The patent changes the cell type parameter from mesenchymal stem cells (MSCs) to pluripotent stem cells (Muse cells), which have higher differentiation potential and regenerative capacity, enabling effective treatment with smaller doses
Solution Approach 2:
Muse cells possess self-differentiation capability that allows them to automatically differentiate into the specific vascular cell types needed at the injury site without external induction, and they self-secrete multiple growth factors to create a regenerative microenvironment
3Reliability
If preventive treatment is performed in early stage aneurysms, then progression risk is reduced, but fundamental therapy for revascularization is not achieved
Solution Approach 1:
The patent enables preliminary action by treating aneurysms in early stages (including 0 cm to 4.9 cm diameter) before rupture occurs, using Muse cell transplantation to promote vascular repair and prevent progression to advanced stages requiring surgery
Solution Approach 2:
Muse cells provide self-service by autonomously differentiating into functional vascular cells and secreting growth factors that promote endogenous vascular repair, achieving fundamental revascularization therapy rather than just symptomatic prevention
Data Source
AI summary
A cell product for prevention and/or treatment of vascular disorders such as aortic aneurysm, comprising a SSEA-3-positive pluripotent stem cell derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell (Muse cell).